[go: up one dir, main page]

WO2001066117A1 - Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal - Google Patents

Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal Download PDF

Info

Publication number
WO2001066117A1
WO2001066117A1 PCT/GB2001/001047 GB0101047W WO0166117A1 WO 2001066117 A1 WO2001066117 A1 WO 2001066117A1 GB 0101047 W GB0101047 W GB 0101047W WO 0166117 A1 WO0166117 A1 WO 0166117A1
Authority
WO
WIPO (PCT)
Prior art keywords
analogue
derivative
use according
metronidazole
hydrogen pump
Prior art date
Application number
PCT/GB2001/001047
Other languages
English (en)
Inventor
Ian Andrew Whitcroft
Andrew Ilchyshyn
Original Assignee
Ian Andrew Whitcroft
Andrew Ilchyshyn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00301951A external-priority patent/EP1133987A1/fr
Application filed by Ian Andrew Whitcroft, Andrew Ilchyshyn filed Critical Ian Andrew Whitcroft
Priority to EP01910045A priority Critical patent/EP1263445A1/fr
Priority to CA002413923A priority patent/CA2413923A1/fr
Priority to AU37628/01A priority patent/AU3762801A/en
Publication of WO2001066117A1 publication Critical patent/WO2001066117A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

  • the present invention relates to the treatment of skin 5 conditions such as rosacea and similar inflammatory dermatoses, and m particular to the treatment of certain kinds of rosacea, and also perioral papular and pustular acne, and other papulopustular dermatoses.
  • Rosacea is a chronic inflammatory disease which affects the face. It is characterised by episodic flushing, erythema, and telangiectasia affecting the cheeks, chin, forehead, and nose. It may be further complicated by inflammatory swelling, papules and pustules.
  • H. Pylori Gram-negative bacterium Helicobacter pylori
  • rosacea and similar inflammatory skin dermatoses can be effectively treated by administering to a patient a treatment regime comprising I) erythromycm, clarithromycm or an analogue or derivative thereof, n) metronidazole or an analogue or derivative thereof, and m) a gastrointestinal hydrogen pump inhibitor, such as omeprazole or an analogue or derivative thereof.
  • the three drugs may be formulated for simultaneous, separate or sequential use.
  • the triple drug combination according to the present invention functions in achieving the desired results.
  • One possibility is that there may be a causal relationship between the dermatoses to be treated and H. pylori , such that eradication of H. pylori may lead to resolution of these dermatoses.
  • Another possibility is that as, certain instances, the presence of H. pylori has been found m pustules on the skin, the triple drug combination may act directly to eradicate that external form of H. pylori .
  • triple drug combination works m another manner, such that any apparent relationship between its use m the present invention and H .pylori may simply be coincidental, such that further study will be necessary elucidate its precise mode of action Description of the Invention
  • the preferred treatment regime comprises erythromycm or clarithromycm, metronidazole and omeprazole, and the most preferred treatment regime comprises clarithromycm, metronidazole and omeprazole.
  • analogues or derivatives of any of these drugs may be used provided that their combined administration achieves the desired result.
  • another similar-acting macrolide antibiotic to erythromycm or clarithromycm may be used, for instance azithromycm or dirithromyc .
  • lanzoprazole or any other drug which acts to inhibits a gastrointestinal hydrogen pump may be used instead of omeprazole.
  • the three drugs may be useful which have a similar or equivalent pharmacological mode of action to the drugs named above.
  • Pharmaceutically- acceptable salt forms of the drugs may also be used.
  • Treatment may be by administration of the three drugs by any suitable means. Conveniently, however, the three drugs will be administered by one or a combination of oral administration, topical application to a patient's skin, or parenteral administration, e.g. intravenous, intramuscular or subcutaneous administration. For instance, one or more of the three drugs may be formulated for administration by a different route to the other drug(s) . Typically, it is desirable to administer omeprazole or an analogue thereof orally, but the other drugs may be formulated for oral, topical or parenteral administration, or any combination thereof. For instance, it may be preferred to administer omeprazole orally and the other two drugs topically, optionally as a combined topical formulation.
  • the triple drug combination may take the form of separate pills containing each of the separate drugs, for simultaneous, separate or sequential administration.
  • the three drugs will be combined into a single dosage form, preferably a tablet, capsule or linctus, for patient convenience.
  • the drugs are incorporated into a suitable pharmaceutically-acceptable carrier.
  • suitable pharmaceutically-acceptable carrier Such formulations have not been disclosed in the prior art, and constitute further aspects of the claimed invention.
  • the relative proportions of the three drugs necessary for effective treatment may vary depending on the route of administration, and the particular patient to be treated.
  • a patient will receive 200 to 600 mg, preferably 300 to 500 mg of erythromycin, clarithromycin or an analogue thereof, 200 to 500 mg, preferably 300 to 500 mg, metronidazole, and 10 to 100 mg, preferably 20 to 60 mg, omeprazole, on a daily basis.
  • a particularly preferred treatment regime comprises about 250 mg erythromycin, clarithromycin or an analogue thereof, about 400 mg metronidazole and about 20 mg omeprazole.
  • Treatment periods vary from patient to patient, from one week to a number of years .
  • a score of one is given if less than half the area involved is affected by that parameter, and a score of two if half or more of the area is affected.
  • the scores for the different parameters in the different facial areas are added together to give a total score for the patient.
  • Each patient was subjected to clinical photography, and then treated with an oral dosage of 20 mg omeprazole, 400 mg metronidazole, and 250 mg clarithromycin for one week.
  • Disease severity scoring and clinical photography were repeated at the end of weeks 6, 12, 18, and 24, and fourteen patients were followed for a period of 52 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation i) d'érythromycine, de clarithromycine ou d'un analogue ou d'un dérivé de ces composés, ii) de métronidazole ou d'un analogue ou d'un dérivé de ce composé, et iii) d'oméprazole ou d'un analogue ou d'un dérivé de ce composé, pour la fabrication d'un médicament destiné au traitement de troubles faisant partie du groupe comprenant des dermatoses inflammatoires, et en particulier l'acné rosacée papulopustuleuse ainsi que des dermatoses papulopustuleuses inflammatoires du même type.
PCT/GB2001/001047 2000-03-09 2001-03-09 Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal WO2001066117A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01910045A EP1263445A1 (fr) 2000-03-09 2001-03-09 Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal
CA002413923A CA2413923A1 (fr) 2000-03-09 2001-03-09 Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal
AU37628/01A AU3762801A (en) 2000-03-09 2001-03-09 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00301951A EP1133987A1 (fr) 2000-03-09 2000-03-09 Traitement de dermatoses inflammatoires avec une combinaison d'erythromycine ou clarithromycine, métronidazole et un inhibiteur des pompes à hydrogène
EP00301951.0 2000-03-09
US18896100P 2000-03-10 2000-03-10
US60/188,961 2000-03-10

Publications (1)

Publication Number Publication Date
WO2001066117A1 true WO2001066117A1 (fr) 2001-09-13

Family

ID=26073033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001047 WO2001066117A1 (fr) 2000-03-09 2001-03-09 Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal

Country Status (4)

Country Link
EP (1) EP1263445A1 (fr)
AU (1) AU3762801A (fr)
CA (1) CA2413923A1 (fr)
WO (1) WO2001066117A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049716A1 (fr) * 2001-12-13 2003-06-19 Ranbaxy Laboratories Limited Formulation topique stable de clarithromycine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472225A2 (fr) * 1985-12-11 1992-02-26 L V M H Recherche Liposomes ou phases lamellaires lipidiques hydratées contenant de la trétinoine
WO1993021920A1 (fr) * 1992-04-24 1993-11-11 Astra Aktiebolag Combinaison synergique d'une substance a effet inhibiteur par rapport a la secretion d'acide gastrique, et d'un antibiotique decomposable par un acide
WO1995018612A1 (fr) * 1994-01-05 1995-07-13 Aktiebolaget Astra Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
WO1996001622A1 (fr) * 1994-07-08 1996-01-25 Astra Aktiebolag Nouvelle preparation pharmaceutique a administration orale contenant un sel magnesien d'omeprazole
WO1996024375A1 (fr) * 1995-02-06 1996-08-15 Astra Aktiebolag Nouvelle forme galenique pharmaceutique orale
JPH10158172A (ja) * 1996-11-29 1998-06-16 Takeshi Azuma 肝性脳症治療剤又は肝性脳症予防剤
WO1999007361A1 (fr) * 1997-08-05 1999-02-18 Millennium Pharmaceuticals, Inc. Procede de lutte contre les bacteries gram negatif chez les mammiferes
WO1999024036A1 (fr) * 1997-11-07 1999-05-20 Aberdeen University Composants ameliorant la penetration dans la peau

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472225A2 (fr) * 1985-12-11 1992-02-26 L V M H Recherche Liposomes ou phases lamellaires lipidiques hydratées contenant de la trétinoine
JPH09110669A (ja) * 1985-12-11 1997-04-28 Lvmh Rech 皮膚病用または化粧品用組成物
WO1993021920A1 (fr) * 1992-04-24 1993-11-11 Astra Aktiebolag Combinaison synergique d'une substance a effet inhibiteur par rapport a la secretion d'acide gastrique, et d'un antibiotique decomposable par un acide
WO1995018612A1 (fr) * 1994-01-05 1995-07-13 Aktiebolaget Astra Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
WO1996001622A1 (fr) * 1994-07-08 1996-01-25 Astra Aktiebolag Nouvelle preparation pharmaceutique a administration orale contenant un sel magnesien d'omeprazole
WO1996024375A1 (fr) * 1995-02-06 1996-08-15 Astra Aktiebolag Nouvelle forme galenique pharmaceutique orale
JPH10158172A (ja) * 1996-11-29 1998-06-16 Takeshi Azuma 肝性脳症治療剤又は肝性脳症予防剤
WO1999007361A1 (fr) * 1997-08-05 1999-02-18 Millennium Pharmaceuticals, Inc. Procede de lutte contre les bacteries gram negatif chez les mammiferes
WO1999024036A1 (fr) * 1997-11-07 1999-05-20 Aberdeen University Composants ameliorant la penetration dans la peau

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALDER, J. D. ET AL: "Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies", AM. J. GASTROENTEROL. (1996), 91(11), 2347-2354, XP000961369 *
DATABASE WPI Week 199834, Derwent World Patents Index; AN 1998-393392, XP002152008 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 11 30 September 1998 (1998-09-30) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31) *
XIA, HARRY HUA-XIANG ET AL: "Prospects for improved therapy for Helicobacter pylori infectio", EXPERT OPIN. INVEST. DRUGS (1996), 5(8), 959-976, XP000961342 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049716A1 (fr) * 2001-12-13 2003-06-19 Ranbaxy Laboratories Limited Formulation topique stable de clarithromycine

Also Published As

Publication number Publication date
AU3762801A (en) 2001-09-17
CA2413923A1 (fr) 2001-09-13
EP1263445A1 (fr) 2002-12-11

Similar Documents

Publication Publication Date Title
CN101843614B (zh) 甲硝哒唑或其药学上可接受的衍生物的用途
US20180264021A1 (en) Treatment of papulopustular rosacea with ivermectin
CA2822320A1 (fr) Composition pour le traitement d'etats pathologiques de la peau
EP1478438B1 (fr) Techniques et compositions destinees au traitement de l'asthme
Schaller et al. State of the art: systemic rosacea management
US9125927B2 (en) Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea
JP2002525266A5 (fr)
US8431601B2 (en) Topical compositions comprising telmesteine for treating dermatological disorders
CN113274384B (zh) 驴食草酚在制备防治溃疡性结肠炎的药物中的应用及其药物
US20210128548A1 (en) External preparation comprising pyridonecarboxylic acid derivative
KR101934767B1 (ko) 신규한 안과용 조성물 및 사용 방법
US20090163455A1 (en) Avermectin/hydrocortisone compositions for treating afflictions of the skin, e.g., rosacea
WO2003089007B1 (fr) Compositions pharmaceutiques comprenant un decongestionnant et d'autres ingredients actifs pour traiter la toux et la grippe
US20200170990A1 (en) Method for treating schnitzler's syndrome
EP1263445A1 (fr) Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal
JP2004513149A (ja) 炎症の治療法
EP1133987A1 (fr) Traitement de dermatoses inflammatoires avec une combinaison d'erythromycine ou clarithromycine, métronidazole et un inhibiteur des pompes à hydrogène
Vardas et al. Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation
EP3251676A1 (fr) Lavement pour application rectale
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
Strauss Complications from flu is a taboo
KR20170099911A (ko) 파라세타몰 주사 제제
WO2023108074A1 (fr) Nouvelles compositions de salvinorine
US20030114534A1 (en) Pharmaceutical preparation for apthous ulcers
WO2001019358A2 (fr) Compositions pharmaceutiques destinees au traitement du psoriasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001910045

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910045

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2413923

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2001910045

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP